Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden: Outlier or predecessor?

Berntsson, Shala G.,1964-Uppsala universitet,Neurologi,Uppsala Univ, Sweden (författare)

Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden : Outlier or predecessor?

Funding Agencies|County Council of Uppsala; Uppsala University
OBJECTIVES: Off-label use of rituximab to treat MS patients in Sweden is high, and the need for long-term safety data may not be met. Our objectives were to assess the rate of rituximab prescription in patients with multiple sclerosis in Sweden and, in addition, to evaluate the safety of rituximab in a single centre for patients with multiple sclerosis.MATERIAL AND METHODS: Review of the Swedish MS register was performed to study the number of MS patients treated with rituximab during the last 6 years. Investigation also included a retrospective review of medical files in search for possible side effects/adverse events in all adult patients with MS treated with rituximab at Uppsala University Hospital.RESULTS: Presently, in Sweden the rate of rituximab prescriptions in relation to other annually started of disease- modifying drugs in MS is 53.5%.CONCLUSIONS: The share of MS patients in Sweden who are treated with rituximab is very high, and also rapidly increasing. Taken into account the off-label use, cases with adverse medical conditions that could possibly be related to rituximab use should be reported thoroughly.

Kristoffersson, AUppsala universitet,Neurologi,Neurology Policlinic, Department of Medical Specialist, Motala General Hospital, Motala, Sweden,Uppsala Univ, Sweden; Motala Gen Hosp, Sweden (författare)
Boström, IngerLinköpings universitet,Avdelningen för neuro- och inflammationsvetenskap,Medicinska fakulteten,Region Östergötland, Neurologiska kliniken i Linköping(Swepub:liu)ingbo67 (författare)
Feresiadou, AmaliaUppsala universitet,Neurologi,Uppsala Univ, Sweden(Swepub:uu)amafe662 (författare)
Burman, Joachim,1974-Uppsala universitet,Neurologi,Uppsala Univ, Sweden(Swepub:uu)joabu293 (författare)
Landtblom, Anne-MarieLinköpings universitet,Uppsala universitet,Neurologi,Department of Clinical and Experimental Medicine, Neurology, Medical Faculty, University of Linköping, Linköping, Sweden; Neurology Policlinic, Department of Medical Specialist, Motala General Hospital, Motala, Sweden,Avdelningen för neuro- och inflammationsvetenskap,Medicinska fakulteten,Region Östergötland, Neurologiska kliniken i Linköping,Uppsala Univ, Sweden; Motala Gen Hosp, Sweden(Swepub:liu)annla55 (författare)
Uppsala universitetNeurologi (creator_code:org_t)

Ingår i:Acta Neurologica Scandinavica: Hindawi Limited138:4, s. 327-3310001-63141600-0404

Av författaren/redakt...: Berntsson, Shala ...; Kristoffersson, ...; Boström, Inger; Feresiadou, Amal ...; Burman, Joachim, ...; Landtblom, Anne- ...

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Neurologi

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.